July 7 (Reuters) - Bristol-Myers Squibb and Co said its combination drug for the treatment of hepatitis C was approved in Japan.
The treatment, which comprises Daklinza and Sunvepra drugs, is meant for patients who are intolerant or have failed to respond to standard medication.
(Reporting By Penumudi Amrutha in Bangalore; Editing by Don Sebastian)
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Bristol-Myers Squibb